SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-010326 to Aditxt, Inc. (ADTX)

Aditxt, Inc.
Date: Sept. 19, 2023 · CIK: 0001726711 · Accession: 0000000000-23-010326

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-274539

Date
September 19, 2023
Author
Amro Albanna
Form
UPLOAD
Company
Aditxt, Inc.

Letter

United States securities and exchange commission logo September 19, 2023 Amro Albanna Chief Executive Officer Aditxt, Inc. 737 N. Fifth Street, Suite 200 Richmond, VA 23219 Re:Aditxt, Inc. Registration Statement on Form S-1 Filed September 15, 2023 File No. 333-274539 Dear Amro Albanna: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sean F. Reid, Esq.

Show Raw Text
United States securities and exchange commission logo
September 19, 2023
Amro Albanna
Chief Executive Officer
Aditxt, Inc.
737 N. Fifth Street, Suite 200
Richmond, VA 23219
Re:Aditxt, Inc.
Registration Statement on Form S-1
Filed September 15, 2023
File No. 333-274539
Dear Amro Albanna:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Sean F. Reid, Esq.